In our current study, we show that novel compounds (decanoic acid and 4-ethyloctanoic acid) function through modulating a DGKA-related pathway commonly affected by lithium and VPA, suggesting that these compounds should be investigated as new treatments for bipolar disorder as well as epilepsy. The gene discussed is DGKA; the disease is epilepsy.